Retrospective Study of Gefitinib as a Second Line Treatment in Lung Cancer.
Loading...
Date
2011-10
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective: To find out response of Gefitinib in terms of
overall survival in advanced non small cell carcinoma lung
progressed after primary treatment. Methods: It is a
retrospective study of clinical data experienced with use of
Gefitinib as a second line treatment of advanced non small
cell carcinoma lung progressed after primary treatment from
period of March 2007 to March 2009 in Burdwan Medical
College and Hospital at Department of Radiotherapy
(Oncology). Results: Among patients treated with Gefitinib
(n – 37) median overall survival was 9.6 months whereas,
patients treated with placebo median survival was 5.3
months. There is a significant survival advantage ( p <
0.001) in Gefitinib group. Conclusion: Gefitinib is a well
tolerated drug and it has a significant survival advantage in
advanced non small cell carcinoma lung progressive after
primary treatment.
Description
Keywords
Citation
Acharyya Santanu, Swaika B, Ghosh Santanu, Roy Amitava, Biswas A. Retrospective Study of Gefitinib as a Second Line Treatment in Lung Cancer. Indian Medical Gazette. 2011 Oct ; 145 (10): 403-406.